Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Neoh, CF; Chen, SC; Lanternier, F; Tio, SY; Halliday, CL; Kidd, SE; Kong, DCM; Meyer, W; Hoenigl, M; Slavin, MA.
Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections.
Clin Microbiol Rev. 2024; 37(2):e0000423 Doi: 10.1128/cmr.00004-23 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz

Hönigl Martin

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

SUMMARYAlthough Scedosporium species and Lomentospora prolificans are uncommon causes of invasive fungal diseases (IFDs), these infections are associated with high mortality and are costly to treat with a limited armamentarium of antifungal drugs. In light of recent advances, including in the area of new antifungals, the present review provides a timely and updated overview of these IFDs, with a focus on the taxonomy, clinical epidemiology, pathogenesis and host immune response, disease manifestations, diagnosis, antifungal susceptibility, and treatment. An expansion of hosts at risk for these difficult-to-treat infections has emerged over the last two decades given the increased use of, and broader population treated with, immunomodulatory and targeted molecular agents as well as wider adoption of antifungal prophylaxis. Clinical presentations differ not only between genera but also across the different Scedosporium species. L. prolificans is intrinsically resistant to most currently available antifungal agents, and the prognosis of immunocompromised patients with lomentosporiosis is poor. Development of, and improved access to, diagnostic modalities for early detection of these rare mold infections is paramount for timely targeted antifungal therapy and surgery if indicated. New antifungal agents (e.g., olorofim, fosmanogepix) with novel mechanisms of action and less cross-resistance to existing classes, availability of formulations for oral administration, and fewer drug-drug interactions are now in late-stage clinical trials, and soon, could extend options to treat scedosporiosis/lomentosporiosis. Much work remains to increase our understanding of these infections, especially in the pediatric setting. Knowledge gaps for future research are highlighted in the review.

Find related publications in this database (using NLM MeSH Indexing)

Humans - administration & dosage

Antifungal Agents - therapeutic use

Scedosporium - drug effects, classification

Drug Resistance, Fungal - administration & dosage

Mycoses - drug therapy, diagnosis, microbiology

Invasive Fungal Infections - drug therapy, diagnosis

Ascomycota - classification, drug effects

Find related publications in this database (Keywords)

fungi

Scedosporium

Lomentospora

© Med Uni Graz • Imprint